Literature DB >> 17675073

aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome.

Mohamad Ali Babai Bigi1, Amir Aslani, Shahab Shahrzad.   

Abstract

BACKGROUND: Risk stratification in Brugada syndrome (BS) is controversial, especially in asymptomatic individuals.
OBJECTIVE: The aim of this study was to evaluate the significance of lead aVR in patients with BS.
METHODS: Twenty-four patients with the electrocardiogram pattern of BS (24 male, mean age 32.1 +/- 13.6 years) and 24 healthy age- and gender-matched controls were studied.
RESULTS: Thirteen patients were symptomatic. The R-wave amplitude or R/q ratio in lead aVR was significantly greater in patients experiencing a recurrence compared with those who did not. The aVR sign was defined as R wave >/= 0.3 mV or R/q >/= 0.75 in lead aVR. Most of the recurrences (78%) were in patients with present aVR sign; 84% of BS patients with present aVR sign had events during follow-up. In contrast, only 27% of BS patients with absent aVR sign had events during follow-up.
CONCLUSION: Our study shows significant correlation between a prominent R wave in lead aVR (aVR sign) and risk for development of arrhythmic events in BS. In the presence of BS, prominent R wave in lead aVR may reflect more right ventricular conduction delay and subsequently more electrical heterogeneity, which in turn is responsible for a higher risk of arrhythmia.

Entities:  

Mesh:

Year:  2007        PMID: 17675073     DOI: 10.1016/j.hrthm.2007.04.017

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  33 in total

1.  aVR - the forgotten lead.

Authors:  Anil George; Pradeep S Arumugham; Vincent M Figueredo
Journal:  Exp Clin Cardiol       Date:  2010

2.  The year of 2007 in electrocardiology.

Authors:  Shlomo Stern
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

3.  Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients.

Authors:  Arash Hashemi; Shahab Shahrzad; Sorayya Shahrzad; Siamak Saber; Samira Taban; Amir Aslani; Zahra Emkanjoo
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

4.  Prognostic significance of T-wave amplitude in lead aVR in heart failure patients with narrow QRS complexes.

Authors:  Kentarou Okuda; Eiichi Watanabe; Kan Sano; Tomoharu Arakawa; Mayumi Yamamoto; Yoshihiro Sobue; Tatsushi Uchiyama; Yukio Ozaki
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

Review 5.  Clinical value of lead aVR.

Authors:  Andrés Ricardo Pérez Riera; Celso Ferreira; Celso Ferreira Filho; Sergio Dubner; Raimundo Barbosa Barros; Francisco Femenía; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

6.  Lateral "Coved" ST-Segment Elevation: Exceptional but Malignant Electrocardiographic Sign in a Patient with Brugada Syndrome.

Authors:  Piotr Kukla; Bartosz Szafran; Andrés Ricardo Pérez-Riera; Marek Jastrzębski; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-02       Impact factor: 1.468

7.  Complete absence of precordial R waves due to absence of left-sided pericardium.

Authors:  Christian Steinberg; Marie-Josée Pelletier; Jean Champagne
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-08-13       Impact factor: 1.468

Review 8.  Clinical utility of aVR-The neglected electrocardiographic lead.

Authors:  Dmitriy Kireyev; Mikhail V Arkhipov; Stephen T Zador; Joseph A Paris; William E Boden
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 9.  Pathogenesis and management of Brugada syndrome.

Authors:  Juan Sieira; Gregory Dendramis; Pedro Brugada
Journal:  Nat Rev Cardiol       Date:  2016-09-15       Impact factor: 32.419

10.  T wave amplitude in lead aVR as a novel diagnostic marker for cardiac sarcoidosis.

Authors:  Yoshihiro Tanaka; Tetsuo Konno; Shohei Yoshida; Toyonobu Tsuda; Kenji Sakata; Hiroshi Furusho; Masayuki Takamura; Kenichi Yoshimura; Masakazu Yamagishi; Kenshi Hayashi
Journal:  Heart Vessels       Date:  2016-07-27       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.